Objective The Jikei Optimal Antihypertensive Treatment (JOINT) study originally evaluated the effect of a fixed-dose formulation of losartan (LOS) (50 mg) plus 12.5 hydrochrolthiazide (HCTZ) for achieving better blood pressure (BP) control in patients with uncontrolled hypertension. This study is a sub-analysis of the JOINT study, focusing on the effect of LOS/HCTZ on the uric acid (UA) metabolism. Methods Among 228 participants in the JOINT study, a total of 164 patients whose blood and urinary UA specimens were available were included in the present analyses. Results Six months after switching from the prior antihypertensive agent(s) to a single tablet formulation of LOS/HCTZ, the overall serum UA concentration (sUA) increased from 6.0 ± 1.6 mg/dL to 6.2 ± 1.6 mg/dL (p=0.029). The urinary UA/creatinine (Cr) ratio increased from 0.45 +/-0.21 to 0.50 +/-0.25 (p=0.014), and the fractional excretion of UA (FEUA) also increased, from 7.1 +/-3.6 to 7.0 +/-4.3, p=0.04). Multivariate regression analyses of the basal parameters showed the change in sUA (ΔUA) to correlate with the basal sUA (β=-0.483, p<0.001), estimated glomerular filtration rate (eGFR) (β=-0.202, p=0.007) and systolic BP (β= 0.147, p=0.038). In addition, the ΔUA also correlated with the changes in the estimated glomerular filtration rate (ΔeGFR) (β=-0.332, p<0.001). When the patients were classified into two groups depending on their basal sUA, those with a basal sUA ! 7 mg/dL exhibited a decrease in their sUA, whereas the rest of those with a sUA <7 mg/dL experienced an increase. Furthermore, patients who had previously been treated with LOS alone had a greater increase in the sUA than those treated with an angiotensin II blocker (ARB) other than LOS alone. Conclusion Antihypertensive therapy with a single tablet formulation of LOS/HCTZ is considered to be a useful option for controlling both BP and sUA, especially in uncontrolled hypertensive patients with hyperuricemia.
Introduction
Hypertension has long been known to be a strong risk factor for cardiovascular diseases. Despite the recommendation for intensified target blood pressure (BP) goals, few patients achieve the recommended target BP. In order to achieve better BP control in patients with refractory hypertension, the majority of hypertension guidelines worldwide recommend the combined use of antihypertensive agents with different pharmacological modes of action (1) (2) (3) .
Recently, the usefulness of thiazide diuretics has been reevaluated for cost-effectiveness. The use of diuretics has been proven to lower BP effectively in large-scale clinical trials such as the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (4) . Diuretics are considered to be particularly effective for those who are considered salt-sensitive. However, diuretics have Division of Kidney and Hypertension, Jikei University School of Medicine, Japan and Division of Nephrology, Saiseikai Central Hospital, Japan not always been accepted as favorable first choice drugs due to their associated adverse reactions, including an increase in the serum uric acid concentration (sUA), hypokalemia and impaired glucose tolerance. These side effects are particularly evident when used at a high dose (2) . However, these effects can be substantially minimized if the drugs are prescribed at a lower dose. A fixed-dose combination formula of LOS (50 mg; the optimal dose) plus a low dose HCTZ (12.5 mg; half of the optimal dose) (LOS/HCTZ) is thus worth evaluating in terms of its BP lowering potency and its effects on UA metabolism.
Among the various types of combinations of agents used for antihypertensive therapy, the combination of an angiotensin II blocker (ARB) and a thiazide diuretic has substantial logical advantages. For instance, the activation of the renin-angiotensin system (RAS) due to diuretic-induced volume depletion can be effectively suppressed by an ARB, thus providing an additive BP-lowering effect. Furthermore, electrolyte disorders elicited by diuretics, such as hypokalemia, may be improved by the anti-aldosterone effect of ARBs. Of interest is the fact that LOS is unique in that it is the only ARB that has a uricosuric effect that leads to a decreased sUA. This effect could be mediated by the inhibition of the urate transporter 1 (URAT-1) in the renal tubules, thus leading to enhanced UA excretion (5-7). Owing to this specific benefit on UA metabolism, LOS has been known to ameliorate diuretic-induced hyperuricemia (8, 9) . The elevation in the sUA induced by diuretics may also be decreased when used in combination with ARBs (5, 8) .
As part of the Jikei Optimal Antihypertensive Treatment (JOINT) study, we have previously reported that LOS/HCTZ exerted an excellent antihypertensive effect after patients switched from their prior antihypertensive drugs (8) . The present trial is an extensional analysis of the results obtained in the JOINT study, focusing on the effect of LOS/HCTZ on the UA metabolism.
Materials and Methods

Patient selection
The study included ambulatory patients aged 20-75 (60.0 +/-11.1) years who did not achieve the target BP of <130/ 80 mmHg despite prior antihypertensive treatment. Patients whose serum creatinine (Cr) concentration exceeded 2.5 mg/ dL, those with chronic liver dysfunction defined as an elevation of alanine aminotransferase three times higher than the upper normal limit, pregnant or lactating women, women who planned to become pregnant, and patients whose doctor in charge judged it inappropriate to enroll, were excluded from the analysis.
Among 228 participants in the JOINT study (8) , a total of 164 patients, whose blood and urinary UA specimens were available, were finally analyzed. Table 1 shows the patient basal characteristics at entry into the study. The ratio of patients whose eGFR exceeded 60 mL/min/1.73 m 2 was 64.6%. Diabetics and dyslipidemic subjects made up 16.5% and 28.7% of the population, respectively. Hyperuricemia was present in 24.4% of patients. ARBs and calcium channel blocker (CCBs) were given to 72.0% and 56.1% of patients, respectively.
Study design
The JOINT study was a multicenter observational selfcontrolled study to evaluate the antihypertensive effect of a fixed-dose combination formulation of LOS/HCTZ (Clinical trial Number by UMIN 000001950) (8) . The study was conducted at 28 medical institutions in the vicinity of Tokyo, including four affiliated hospitals of the Jikei University School of Medicine. All institutions received prior ethics committee and/or institutional review board approval, and the trial was conducted in accordance with the principles of Good Clinical Practice and the ethical principles of the concurrent Declaration of Helsinki, which also protected the privacy of the patients. All patients gave their written informed consent before study enrollment.
Antihypertensive treatment
All patients were previously treated with one or more antihypertensive agents on an outpatient basis. The protocol for the administration of a fixed formulation tablet of LOS 50 mg/HCTZ 12.5 mg was the following: if the patient was being treated with either an ARB or CCB alone or together, a fixed dose of LOS/HCTZ was substituted for either drug or the combination. If the patient was being treated with three drugs, including RAS inhibitors, the RAS inhibitor was switched to LOS/HCTZ. In all of the protocol patterns, LOS/HCTZ was administered once a day in the morning. For ethical reasons, in cases where the target BP of 130/80 mmHg was not achieved, additional antihypertensive drugs were used at the discretion of the patient's doctor.
At entry and after 6 months of the treatment, the systolic and diastolic BP, sUA, Cr concentration, fractional excretion of uric acid (FEUA), urine UA/Cr ratio and estimated glomerular filtration rate (eGFR) were measured. Comparisons were then made between the beginning and at the end of the study periods.
Statistical analysis
The paired and unpaired Student's t-test, and univariate and multivariate regression analyses were used as deemed necessary to analyze the data. These analyses were carried out with Jump 9.0 software program. The computer used for the analysis was a Dynabook Satellite 2590X (Toshiba, Tokyo, Japan).
The data are presented as the means +/-standard deviation (SD) unless otherwise indicated. A p value <0.05 was considered to be statistically significant. Table 2 shows the changes in the clinical parameters in response to antihypertensive treatment with LOS/HCTZ. Six months after switching from the baseline medications to LOS/HCTZ, significant decreases in the clinical BP were observed in both the systolic (145 +/-12 to 134 +/-14 mmHg) and diastolic BP (87 +/-9 to 80 +/-10 mmHg, both comparisons p<0.001). There was an increase in the serum Cr concentration (0.97 +/-o.41 to 1.02 +/-0.47 mg/dL, p< 0.001), which was associated with a decrease in the eGFR (from 65.9 +/-21.4 to 63.4 +/-20.8 mL/min/1.73 m 2 , p< 0.001). Additionally, there was a significant increase in the sUA (from 6.0 +/-1.6 to 6.2 +/-1.6 mg/dL, p=0.029), urine UA/Cr ratio (from 0.45 +/-0.21 to 0.50 +/-0.25, p=0.014) and FEUA (from 7.1 +/-3.4 to 7.9 +/-4.2, p=0.004).
Results
Changes in various parameters in response to the treatment with LOS/HCTZ
Analyses of serum and urinary UA metabolism Table 3 shows the results of both univariate and multivariate regression analyses on baseline parameters used to predict the change in sUA (ΔUA). Among such variables, the multivariate regression analyses showed that the ΔUA was correlated with the basal sUA (β=-0.483, p<0.001), eGFR (β=-0.202, p=0.007) and systolic BP (β=0.147, p=0.038). In addition, the ΔUA was negatively correlated with the changes in the eGFR (ΔeGFR) (β=-0.332, p<0.001). The ΔUA tended to be positively associated with the baseline FEUA (R=0.148, p=0.058) Table 4 shows the results of the univariate and multivariate regression analyses of the changes in various parameters that explain the ΔUA. The multivariate analysis showed that the ΔUA was negatively correlated with the ΔeGFR (β= -0.332, p<0.001). In the univariate regression analysis, the ΔUA tended to be positively associated with the ΔFEUA (R=0.137, p=0.087). Fig. 1 . depicts the comparison of parameters between the two groups after they were divided into two quantitatively different categories. Patients with hyperuricemia (sUA ! 7 mg/dL) at the beginning of the study were good responders who showed a decrease in the sUA after six months of treatment with LOS/HCTZ. None of the other parameters showed any significant difference. Fig. 2 depicts the differential effects of previous treatment with LOS compared to treatment with ARBs other than LOS. Patients who had previously been treated with LOS alone had a significant increase in the sUA in response to LOS/HCTZ (from 6.3 +/-1.5 at entry to 6.7 +/-1.6 mg/dL at six months, n=29, p=0.021). However, the patients previously treated with an ARB other than LOS alone had no such effect (from 6.0 +/-1.6 at entry to 6.1 +/-1.5 mg/dL at six months, n=89, p=0.248). (Fig. 2, left panel) . The increase in the sUA (ΔUA) in patients previously treated with LOS alone was comparable to that in those who were previously treated with ARBs other than LOS alone (ΔUA: 0.43 +/-0.95 in the LOS-pretreated vs. 0.13 +/-1.09 in the non-LOS-pretreated, p=0.029) (Fig. 2, right panel) .
Effect of previous treatment with LOS on hyperuricemia
Discussion
Adverse events associated with thiazide diuretics, such as hyperuricemia, electrolyte abnormalities and abnormal glucose or lipid metabolism, increase in a dose-dependent man- ner. In contrast, the maximum antihypertensive effect of diuretics is not dose-dependent. In fact, the most potent BP lowering is achieved at a dose lower than that required for the maximum diuretic effect (2) . Of importance is the fact that thiazide-induced hyperuricemia can be associated with increased cardiovascular risk. For example, in the WORK-SITE study that examined 7,978 mild to moderately hypertensive patients to determine whether the pretreatment and/ or in-treatment sUA is associated with cardiovascular events, an increase in the sUA during the treatment was significantly and directly associated with cardiovascular events, independent of diuretic use and other cardiovascular risk factors (9) . Moreover, in the Systolic Hypertension in Elderly Program (SHEP) trial, the reduction in coronary artery disease events achieved by treatment with a diuretic, chlorthalidone, was completely abolished in those patients whose sUA increased ! 60 μmol/L during treatment, who had a similar risk of coronary events as the placebo group (10) . These studies suggest that diuretics increased UA reabsorption in the proximal tubule, while causing hyperuricemia, by which the benefits of diuretics in preventing cardiovascular disease may be partially offset.
Of note, LOS is known to enhance the urinary excretion of UA by inhibiting the reabsorption of UA through the URAT-1 transporter that is present on the luminal side of the renal tubules. A study using URAT1-expressing Xenopus oocytes has shown that some ARBs, including LOS, have cisinhibitory and trans-stimulatory effects on URAT1, while others do not. The authors suggested that this could explain the differences observed in the clinical effects of ARBs on sUA (11) . Moreover, in the landmark LIFE study, it was suggested that the beneficial effects of LOS in preventing cardiovascular disease may be attributable to its improvement of the sUA (12) . Namely, a Cox regression model including a time-varying covariate was used to assess the relationship of the sUA and treatment regimens with the LIFE primary composite outcome. The analyses showed that baseline sUA was significantly associated with increased cardiovascular events, and that the contribution of the sUA to the treatment effect of LOS on the primary endpoint was 29%.
In the present study, despite the fact that the overall sUA increased the sUA, it was significantly decreased in patients with hyperuricemia ( Fig. 1) , suggesting that LOS/HCTZ may be a useful option for preventing cardiovascular disease There was a decrease in the e-GFR in response to the treatment with LOS/HCTZ. This decrease in the e-GFR could be accounted for by either the spontaneous progression of renal impairment in patients with refractory hypertension or the deleterious effect of HCTZ, which might have induced volume contraction (Table 3) . However, of note in this sub-analysis, the substantial increase in both the urine UA/Cr ratio and the FEUA were derived from the uricosuric action of LOS. Despite the fact that the overall sUA increased, patients with a sUA exceeding 7 mg/dL experienced a significant sUA lowering effect, thus suggesting this combination to still be interesting and advantageous for controlling the UA metabolism in patients with refractory hypertension.
The ΔUA tended to be positively correlated with the baseline FEUA, thus indicating that the sUA increased in patients with a high baseline FEUA (Table 3) . One may speculate that in patients with a high baseline FEUA, LOS further enhanced the UA excretion, and thus, the reabsorption of UA by HCTZ resulted in an increase in the sUA. It has been reported that, in Japanese patients with hyperuricemia, 60% of cases are caused by decreased UA excretion and 25% by a mixture of excessive production and decreased excretion of UA, thus indicating that a total of 85% tended to have decreased urinary UA excretion. Therefore, one can assume that LOS-enhanced UA excretion can be effective in the majority of patients with hyperuricemia (13-15).
There was an almost significantly negative correlation between the ΔFEUA and the ΔUA ( Table 4 ). The sUA decreased in patients with an increased FEUA after six months. This suggests that the improvement in the sUA was attributable to the enhanced FEUA, and that benefits in reducing the sUA can be attained when LOS-induced UA excretion exceeds HCTZ-induced reabsorption of UA.
A significant increase in the sUA was observed in patients receiving LOS at baseline (Fig. 2) . It is assumed that the excretion of UA had already been enhanced in patients who were being treated with LOS at baseline, and the addition of HCTZ increased the reabsorption of UA, which eventually increased the UA level in this group of patients. On the other hand, in patients who were switched from other ARBs, the effects of LOS and HCTZ may be offset, resulting in no change in the sUA. Hamada et al. compared the effects of various types of combination therapies using a low-dose diuretic and an ARB on the sUA in hypertensive patients without hyperuricemia (14) . They found that the sUA was increased with candesartan/HCTZ and telmisartan/ HCTZ therapy, but not with LOS/HCTZ, thus suggesting that the difference can be account for by the inhibitory effect of LOS on URAT1.
Taking all of these findings into consideration, it can be concluded that the combination of LOS/HCTZ can be useful in hypertensive patients with concomitant hyperuricemia.
Conclusion
Antihypertensive therapy with a single tablet formulation of LOS/HCTZ was therefore found to be a useful option for controlling refractory hypertension, especially in patients with hyperuricemia.
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